The proposition Congress is being asked to consider
Federal law already recognizes an individual sponsor and a sponsor-investigator. Yet a statutory category does not guarantee an accessible pathway for a competent independent investigator without institutional funding or operational infrastructure. The proposed Act would establish predictable procedural access, sponsor-support services, and participant rights while leaving product safety, honest consent, and scientifically defensible evidence as binding responsibilities. F01F02F05
The legislative question is precise: can federal law create a scalable research pathway for appropriate low- and proportionate-risk work, supply better administrative assistance to community investigators, and provide transparent review and appeal mechanisms, without creating a regulatory loophole for drug marketing or undisclosed human experimentation? The answer requires choices about legal eligibility, product categories, federal-state relationships, funding, and enforcement—not simply a declaration of liberty.
The initiative asks policymakers to treat citizens as research contributors with agency and accountable obligations. The proposed architecture has three branches: open scientific inquiry and educational research; sponsor-supported observational and data research; and interventional clinical investigations carried out only through the applicable, specifically defined legal route. A participant's willingness cannot automatically transform the third category into the first. F01F10F25
The four enforceable promises
First, access to a classification decision: an individual should be able to submit a sufficiently described research proposal and receive a reasoned written determination of which federal rules and exemptions apply. The agency should publish the criteria and handle complete requests within a defined deadline. The enforceable object is a decision, not a promise of a favorable result. This is a proposed addition to present administrative practice. F01F03
Second, access to competent collaboration: Congress can authorize grants or a public-interest sponsor-support network that helps independent teams with protocol design, data management, ethics review, analytic methods, and appropriate safety systems. A directory of voluntary qualified clinicians and recognized research service providers could lower logistical barriers while maintaining professional responsibility. The statute must avoid conscripting professionals or preempting state medical law by implication. F02F05F24
Third, rights over participation and data: a federal research-data charter could define an auditable record of specific permissions, future-use limitations, participant access and portability, and duties of research-data recipients, including users outside HIPAA-covered relationships. A technical token could represent permission but would not by itself make the underlying information anonymous or confer statutory rights. F14F15F16F17
Fourth, accountability that makes consent meaningful: the Act should differentiate the inherent uncertainty accepted in a properly explained investigation from preventable negligence, deliberate deception, product defects, contaminated supply, and misconduct. It should require responsible sponsors, adverse-event pathways, records, and where justified an injury-support mechanism. This is legislative design rather than an existing entitlement. F04F07F08
The existing law that provides a foundation
The federal IND framework already provides a route through which qualifying studies may proceed. The regulations at 21 CFR §312.2 identify applicability and exemptions; §312.3 identifies sponsors; §312.40 describes when an investigation may start. FDA-regulated investigations can also require informed consent and IRB review under distinct rules. An effective bill must engage these sections directly instead of pretending none exist. F01F02F03F07F09
Congress has enacted a narrow Right to Try law for eligible patients and investigational products. Its structure shows a legislature can make specifically defined exceptions, but the statute is not a general right to all investigational substances. A Right to Research proposal should be judged by its own eligibility, governance and supply provisions, not by analogy alone. A Congressional Research Service comparison of clinical trials, expanded access, and Right to Try is an appropriate first staff resource. F11F22F23
The 2024 FDA guidance on decentralized clinical trials and 2025 final E6(R3) Good Clinical Practice guidance provide foundations for modern, participant-centered research, technology use, and quality-by-design. Guidance does not itself create a new statutory exception. The opportunity is to build institutional capacity and clearly scoped legislative change on top of that baseline. F18F19
The congressional decision points
Congress must choose whether the initiative primarily reforms the existing IND system or creates a separately named statutory research route. A narrow model could guarantee written classification, small-sponsor assistance and clarified review options within present law. A more ambitious model could create new adult-eligible investigational categories with tailored oversight, but that choice would have significantly higher product-quality and liability design costs.
The second choice is federalism: what conduct and actors would the new law affect in states with separate licensing, pharmacy, practice-of-medicine, data privacy and tort requirements? A clause saying 'federal law preempts everything' would be both overbroad and legally fragile. The draft should name precise conflicts, preserve protections that Congress does not intend to displace, and ask legislative counsel to analyze insurance and state civil remedies. L02
Third is implementation and measurement. Assign FDA, HHS/OHRP, NIH or another specifically named official the required regulation, assistance program and research evaluation; designate a congressional reporting deadline; fund the work; and publish transparent metrics. Without an accountable agency, procedural standards, appropriations and judicial or administrative review, the Act risks becoming a slogan.
The immediate ask of a congressional office is to request a legislative-counsel discussion and a committee staff briefing; obtain FDA and HHS technical assistance on authority, scientific standards, and pilot feasibility; commission a comparison of narrower and broader legislative alternatives; and solicit independent participants and clinicians for testimony. The petition count can show civic interest, but it is not a legal prerequisite for filing legislation.
The strongest near-term pilot
The least speculative first demonstration is not a mass drug-intervention program. It is a federally supported research-access pilot serving individual sponsors with regulatory classification advice, protocol templates, consent language, ethics-review navigation, and privacy-safe observational research infrastructure. Outcomes could include time to complete determination, cost borne by applicants, number of appropriately screened projects, independent review access, participant comprehension, safety findings and proportion of results posted.
An eventual interventional pilot could be considered only under defined lawful sponsorship and study-specific safeguards. Pilot selection should avoid product conflicts of interest, marketing claims, and regulatory arbitrage. A credible movement makes scientific participation easier precisely by proving it can document who was responsible, why a study was permitted, what occurred, and what the evidence really shows. F04F05F19